MMSI - Earnings announcements

Financial Highlights† Reported revenue of $381.9 million, up 7%Constant currency revenue* and constant currency revenue, organic* up 5% and up 3%, respectively Constant currency revenue, organic* increased 4%, excluding revenue from divested product line GAAP operating margin of 11.6%, compared to 11.5% in prior year periodNon-GAAP operating margin* of 19.7%, compared to 19.3% in prior year periodGAAP EPS $0.68, up 39%Non-GAAP EPS* $0.94, up 9%Free cash flow* generation of $24.7 million, up 26% Business Developments On February 17, 2026, Merit sold certain assets related to the DualCap® product line to Health Line International Corporation for a purchase price of $28 million, of which $25

SOUTH JORDAN, Utah, April 02, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2026, after the close of the stock market on Thursday, April 30, 2026. Merit plans to hold its investor conference call on the same day (Thursday, April 30, 2026) at 4:30 p.m. Eastern (3:30 p.m. Central, 2:30 p.m. Mountain, and 1:30 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed using this link. A link to bo

SOUTH JORDAN, Utah, April 01, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced it has acquired View Point Medical, Inc. (View Point). Through a merger transaction, View Point is now a wholly-owned subsidiary of Merit. View Point, located in Carlsbad, California, manufactures the OneMark® Detection Imaging System and OneMark Tissue Markers. The aggregate transaction consideration, including the assumption of ViewPoint liabilities, is approximately $140 million. Of that amount, $90 million was paid in cash at closing and two deferred payments of $25 million each are scheduled to be paid not later than the first and

Fourth Quarter Highlights† Reported revenue of $393.9 million, up 11%Constant currency revenue* and constant currency revenue, organic* up 10% and up 7%, respectivelyGAAP operating margin of 13.8%, compared to 10.3% in prior year periodNon-GAAP operating margin* of 21.0%, compared to 19.6% in prior year periodGAAP EPS $0.63, up 37%Non-GAAP EPS* $1.04, up 12%Free cash flow* generation of $74.0 million, up 13% Fiscal Year 2025 Highlights† Reported revenue of $1.516 billion, up 12%Constant currency revenue* and constant currency revenue, organic* up 11% and up 7%, respectivelyGAAP operating margin of 12.2%, compared to 11.5% in prior yearNon-GAAP operating margin* of 20.3%, compared to 19.0%

SOUTH JORDAN, Utah, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader in healthcare technology, today announced that its Board of Directors unanimously appointed F. Ann Millner, Ed.D., formerly Merit's Lead Independent Director, as Chair of the Board effective January 5, 2026. Dr. Millner has served as a director of Merit since 2015 and as the Lead Independent Director since July 2021. She previously served as the Chair of Merit's Governance and Sustainability Committee. Dr. Millner currently serves as a member of the Utah State Senate, to which she was elected in 2015. She served as the President of Weber State University from 2002 through 2012

Highlights† Reported revenue of $384.2 million, up 13.0%Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 7.8%, respectivelyGAAP operating margin of 11.1%, compared to 11.0% in prior year periodNon-GAAP operating margin* of 19.7%, compared to 19.2% in prior year periodGAAP EPS $0.46, down 3.0%Non-GAAP EPS* $0.92, up 6.7%Free cash flow* generation of $141.6 million over first nine months of 2025, up 17.6% year-over-year † Comparisons above are calculated for the current quarter compared with the third quarter of 2024, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts. * Const

SOUTH JORDAN, Utah, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2025, after the close of the stock market on Thursday, October 30, 2025. Merit plans to hold its investor conference call on the same day (Thursday, October 30, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed

Highlights† Reported revenue of $382.5 million, up 13.2%Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 6.7%, respectivelyGAAP operating margin of 12.3%, compared to 13.6% in prior year periodNon-GAAP operating margin* of 21.2%, compared to 20.1% in prior year periodGAAP EPS $0.54, down 11.6%Non-GAAP EPS* $1.01, up 9.8%Free cash flow* generation of $89.1 million over first six months of 2025, up 8.1% year-over-yearAcquired Biolife Delaware, L.L.C. ("Biolife"), a manufacturer of hemostatic devices branded as StatSeal® and WoundSeal®Martha Aronson named as new President and Chief Executive Officer, effective October 3, 2025 † Comparisons above are calculate

Fred Lampropoulos will continue to serve as Chairman of Merit's Board of Directors Merit announces preliminary unaudited revenue for the quarter ended June 30, 2025 SOUTH JORDAN, Utah, July 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, announced today the appointment of Martha Aronson as Merit's new President and Chief Executive Officer, effective October 3, 2025. Fred P. Lampropoulos will remain as Chairman of the Board, President and CEO of Merit through October 3, 2025. Upon Ms. Aronson's appointment, Mr. Lampropoulos will continue to serve as Chairman of the Board. "I am pleased to welcome Martha to Merit," said Mr.

SOUTH JORDAN, Utah, July 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2025, after the close of the stock market on Wednesday, July 30, 2025. Merit plans to hold its investor conference call on the same day (Wednesday, July 30, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed using th

First Quarter Highlights† Reported revenue of $355.4 million, up 9.8%Constant currency revenue* and constant currency revenue, organic* up 10.9% and up 6.0%, respectivelyGAAP operating margin of 11.5%, compared to 11.1% in prior year periodNon-GAAP operating margin* of 19.3%, compared to 17.0% in prior year periodGAAP EPS $0.49, up 2.0%Non-GAAP EPS* $0.86, up 14.8%Free cash flow* generation of $19.5 million, down 20.5% † Comparisons above are calculated for the current quarter compared with the first quarter of 2024, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts. * Constant currency revenue; constant cu

SOUTH JORDAN, Utah, April 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2025, after the close of the stock market on Thursday, April 24, 2025. Merit plans to hold its investor conference call on the same day (Thursday, April 24, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed us

Fourth Quarter Highlights† Reported revenue of $355.2 million, up 9.4%Constant currency revenue* and constant currency revenue, organic* up 10.1% and up 6.1%, respectivelyGAAP operating margin of 10.3%, compared to 10.4% in prior year periodNon-GAAP operating margin* of 19.6%, compared to 16.6% in prior year periodGAAP EPS $0.46, down 2.6%,Non-GAAP EPS* $0.93, up 25.8%, andFree cash flow* generation of $65.3 million, up 18.4% Fiscal Year 2024 Highlights† Reported revenue of $1.357 billion, up 7.9%Constant currency revenue* and constant currency revenue, organic* up 8.5% and up 6.0%, respectivelyGAAP operating margin of 11.5 %, compared to 9.9% in prior yearNon-GAAP opera

2024 preliminary unaudited revenue in the range of approximately $1.355 billion - $1.357 billion, up approximately 7.7% - 7.9% year-over-year2024 preliminary constant currency revenue* increased in the range of approximately 8.4% - 8.6% year over year2024 financial results and 2025 guidance to be released February 25, 2025 * Constant currency revenue is a non-GAAP financial measure. A reconciliation of this financial measure to its most directly comparable GAAP financial measure is included under the heading "Non-GAAP Financial Measure" below. SOUTH JORDAN, Utah, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of hea

Unique cell-impermeable1 design extends life-saving treatment for dialysis patientsMerit to host a WRAPSODY informational call on January 28, 2025 SOUTH JORDAN, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that the WRAPSODY® Cell-Impermeable Endoprosthesis has received premarket approval from the US Food and Drug Administration (FDA). With this approval, Merit can begin commercialization of the device in the USA in 2025. WRAPSODY is designed to extend long-term vessel patency in dialysis patients2. Many patients undergoing dialysis rely on a vascular acce

Third Quarter 2024 Highlights† Reported revenue of $339.8 million, up 7.8%Constant currency revenue* and constant currency revenue, organic* up 7.9% and up 5.7%, respectivelyGAAP operating margin of 11.0%, compared to 11.1% in prior year periodNon-GAAP operating margin* of 19.2%, compared to 17.4% in prior year periodGAAP EPS $0.48, up 8.0%, and non-GAAP EPS* $0.86, up 21.1%Generated free cash flow* $120 million over the first nine months of 2024, up 116% year-over-yearCompleted the acquisition of certain assets from EndoGastric Solutions, Inc., which included the EsophyX® Z+, a device intended for the treatment of chronic gastroesophageal reflux diseaseAnnounced positive 6-month findings

SOUTH JORDAN, Utah, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2024, after the close of the stock market on Wednesday, October 30, 2024. Merit will hold its investor conference call on the same day (Wednesday, October 30, 2024) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide dec

Second Quarter 2024 Highlights† Reported revenue of $338.0 million, up 5.6%Constant currency revenue* up 6.6%Constant currency revenue, organic,* up 5.0%GAAP operating margin of 13.6%, compared to 9.0% in prior year periodNon-GAAP operating margin* of 20.1%, compared to 19.1% in prior year periodGAAP EPS $0.61, up 75.7%Non-GAAP EPS* $0.92, up 16.8% † Comparisons noted in the bullet points are calculated for the current quarter compared with the same prior year period unless otherwise specified. * The constant currency revenue; constant currency revenue, organic; non-GAAP gross profit and margin; non-GAAP operating income and margin; non-GAAP net income; non-GAAP EPS; and

Asset acquisition expands Merit's endoscopy portfolio with a minimally invasive solution for patients suffering from chronic gastroesophageal reflux disease (GERD). Asset acquisition projected to add approximately $30 million of revenue, on an annualized basis, in key gastrointestinal endoscopy market that leverages existing commercial footprint.  Merit reaffirms full-year 2024 financial guidance on standalone basis and updates full-year 2024 financial guidance to include projected partial-year impact from this acquisition. SOUTH JORDAN, Utah, July 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announ

SOUTH JORDAN, Utah, June 18, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2024, after the close of the stock market on Thursday, August 1, 2024. Merit will hold its investor conference call on the same day (Thursday, August 1, 2024) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed

Q1 2024 reported revenue of $323.5 million, up 8.7% compared to Q1 2023Q1 2024 constant currency revenue* up 9.3% compared to Q1 2023Q1 2024 constant currency revenue, organic* up 7.0% compared to Q1 2023Q1 2024 GAAP operating margin of 11.1%, compared to 8.9% in Q1 2023Q1 2024 non-GAAP operating margin* of 17.3%, compared to 16.1% in Q1 2023Q1 2024 GAAP EPS $0.48, up 35.5%, compared to $0.36 in Q1 2023Q1 2024 non-GAAP EPS* $0.77, up 18.7%, compared to $0.64 in Q1 2023 * Constant currency revenue; constant currency revenue, organic; non-GAAP gross profit and margin; non-GAAP operating income and margin; non-GAAP net income; non-GAAP EPS; and free cash flow are non-GAAP financial measures. A

SOUTH JORDAN, Utah, March 18, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2024, after the close of the stock market on Tuesday, April 30, 2024. Merit will hold its investor conference call on the same day (Tuesday, April 30, 2024) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed using this

Q4 2023 reported revenue of $324.5 million, up 10.6% year-over-yearQ4 2023 constant currency revenue* up 10.3% year-over-yearQ4 2023 constant currency revenue, organic* up 8.3% year-over-yearQ4 2023 GAAP operating margin of 10.4%, compared to 10.4% in Q4 2022Q4 2023 non-GAAP operating margin* of 18.2%, compared to 17.8% in Q4 2022Q4 2023 GAAP EPS $0.47, compared to $0.58 in Q4 2022Q4 2023 non-GAAP EPS* $0.81, compared to $0.79 in Q4 2022Issues fiscal year 2024 financial guidance *  Constant currency revenue; constant currency revenue, organic; non-GAAP EPS; non-GAAP net income; non-GAAP operating income and margin; non-GAAP gross profit and margin; and free cash flow are non-GAAP financial

SOUTH JORDAN, Utah, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, today introduced its Continued Growth Initiatives Program and related financial targets for the three-year period ending December 31, 2026. Merit's new multi-year financial targets are: Total revenue increase at a compound annual growth rate (CAGR) of 5% to 7% on an organic, constant currency, basis* for the three-year period ending December 31, 2026.Non-GAAP operating margin* of 20.0% to 22.0% for the year ending December 31, 2026.Cumulative free cash flow* generation of at least $400 million for the three-year

2023 reported preliminary unaudited revenue in the range of approximately $1.255 billion - $1.259 billion, up approximately 9.0% - 9.4% year-over-year2023 preliminary unaudited constant currency revenue* in the range of up approximately 9.6% - 9.9% year over year2023 financial results and 2024 guidance to be released February 28, 2024 *  Constant currency revenue is a non-GAAP financial measure. A reconciliation of this financial measure to its most directly comparable GAAP financial measure is included under the heading "Non-GAAP Financial Measure" below. SOUTH JORDAN, Utah, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufac

Q3 2023 reported revenue of $315.2 million, up 9.8% year-over-yearQ3 2023 constant currency revenue* up 9.7% year over yearQ3 2023 constant currency revenue, organic* up 7.1% year-over-yearQ3 2023 GAAP operating margin of 11.1%, compared to 6.5% in Q3 2022Q3 2023 non-GAAP operating margin* of 18.3%, compared to 16.1% in Q3 2022Q3 2023 GAAP EPS $0.44, compared to $0.27 in Q3 2022Q3 2023 non-GAAP EPS* of $0.75, compared to $0.64 in Q3 2022Raises fiscal year 2023 financial guidance *  Constant currency revenue; constant currency revenue, organic; non-GAAP EPS; non-GAAP net income; non-GAAP operating income and margin; non-GAAP gross profit and margin; and free cash flow are non-GAA

SOUTH JORDAN, Utah, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2023, after the close of the stock market on Thursday, October 26, 2023. Merit will hold its investor conference call on the same day (Thursday, October 26, 2023) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be acces

Q2 2023 reported revenue of $320.1 million, up 8.5% year-over-yearQ2 2023 constant currency revenue* up 9.4% year over yearQ2 2023 constant currency revenue, organic* up 9.1% year-over-yearQ2 2023 GAAP operating margin of 9.0%, compared to 7.9% in Q2 2022Q2 2023 non-GAAP operating margin* of 19.9%, compared to 19.1% in Q2 2022Q2 2023 GAAP EPS $0.35, compared to $0.27 in Q2 2022Q2 2023 non-GAAP EPS* of $0.81, compared to $0.73 in Q2 2022 *  Constant currency revenue; constant currency revenue, organic; non-GAAP EPS; non-GAAP net income; non-GAAP operating income and margin; non-GAAP gross profit and margin; and free cash flow are non-GAAP financial measures. A reconciliation of these financi

SOUTH JORDAN, Utah, July 06, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2023, after the close of the stock market on Tuesday, July 25, 2023. Merit will hold its investor conference call on the same day (Tuesday, July 25, 2023) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed using thi

Q1 2023 reported revenue of $297.6 million, up 8.0% compared to Q1 2022Q1 2023 constant currency revenue, organic* up 9.8% compared to Q1 2022Q1 2023 GAAP operating margin of 8.9%, compared to 5.5% in Q1 2022Q1 2023 non-GAAP operating margin* of 16.1%, compared to 14.6% in Q1 2022Q1 2023 GAAP EPS $0.36, compared to $0.18 in Q1 2022Q1 2023 non-GAAP EPS* of $0.64, compared to $0.53 in Q1 2022 *  Constant currency revenue; constant currency revenue, organic; non-GAAP EPS; non-GAAP net income; non-GAAP operating income and margin; non-GAAP gross profit and margin; and free cash flow are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparabl

SOUTH JORDAN, Utah, April 06, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2023, after the close of the stock market on Wednesday, April 26, 2023. Merit will hold its investor conference call on the same day (Wednesday, April 26, 2023) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed using t

SOUTH JORDAN, Utah, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the fourth quarter and year ended December 31, 2022, and issue fiscal year 2023 guidance after the close of the stock market on Wednesday, February 22, 2023. Merit will hold its investor conference call on the same day (Wednesday, February 22, 2023) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in deta

Q3 2022 reported revenue of $287.2 million, up 7.5% compared to Q3 2021 Q3 2022 constant currency revenue, organic* up 10.5% compared to Q3 2021 Q3 2022 GAAP operating margin of 6.5%, compared to 6.0% in Q3 2021 Q3 2022 non-GAAP operating margin* of 16.1%, compared to 14.8% in Q3 2021 Q3 2022 GAAP EPS $0.27, compared to $0.21 in Q3 2021 Q3 2022 non-GAAP EPS* of $0.64, compared to $0.52 in Q3 2021 * Constant currency revenue; constant currency revenue, organic; non-GAAP EPS; non-GAAP net income; non-GAAP operating income and margin; non-GAAP gross profit and margin; and free cash flow are non-GAAP financial measures. A reconciliation of these financ

SOUTH JORDAN, Utah, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2022, after the close of the stock market on Wednesday, October 26, 2022. Merit will hold its investor conference call on the same day (Wednesday, October 26, 2022) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed

Q2 2022 reported revenue of $295.0 million, up 5.2% compared to Q2 2021Q2 2022 constant currency revenue, organic* up 7.4% compared to Q2 2021Q2 2022 GAAP operating margin of 7.9%, compared to 3.2% in Q2 2021Q2 2022 non-GAAP operating margin of 19.1%, compared to 16.3% in Q2 2021Q2 2022 GAAP EPS $0.27, compared to $0.09 in Q2 2021Q2 2022 non-GAAP EPS* of $0.73, compared to $0.62 in Q2 2021 *  Constant currency revenue; constant currency revenue, organic; non-GAAP EPS; non-GAAP net income; non-GAAP operating income and margin; non-GAAP gross margin; and free cash flow are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparable GAAP financia

SOUTH JORDAN, Utah, July 14, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2022, after the close of the stock market on Wednesday, July 27, 2022. Merit will hold its investor conference call on the same day (Wednesday, July 27, 2022) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed

Q1 2022 reported revenue of $275.4 million, up 10.6% compared to Q1 2021Q1 2022 constant currency revenue, organic* up 11.3% compared to Q1 2021Q1 2022 GAAP EPS $0.18, compared to $0.19 in Q1 2021Q1 2022 non-GAAP EPS* of $0.53, compared to $0.52 in Q1 2021 *  Constant currency revenue; constant currency revenue, organic; non-GAAP EPS; non-GAAP net income; non-GAAP operating income and margin; non-GAAP gross margin; and free cash flow are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparable GAAP financial measures is included under the heading "Non-GAAP Financial Measures" below. SOUTH JORDAN, Utah, April 27, 2022 (GLO

SOUTH JORDAN, Utah, April 13, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it will release its financial results for the quarter ended March 31, 2022, after the close of the stock market on Wednesday, April 27, 2022. Merit will hold its investor conference call (conference ID 3580638) on the same day (Wednesday, April 27, 2022) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). The telephone numbers to ca

SOUTH JORDAN, Utah, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it will release its financial results for the fourth quarter and year ended December 31, 2021, and issue FY 2022 guidance after the close of the stock market on Thursday, February 24, 2022. Merit will hold its investor conference call (conference ID 5259615) on the same day (Thursday, February 24, 2022) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, an

Q3 2021 reported revenue of $267.0 million, up 9.4% compared to Q3 2020Q3 2021 constant currency revenue, organic* up 8.8% compared to Q3 2020Q3 2021 GAAP EPS of $0.21, compared to GAAP loss per share of ($0.05) in Q3 2020Q3 2021 non-GAAP EPS* of $0.52, compared to $0.42 in Q3 2020 *  Constant currency revenue; constant currency revenue, organic; core revenue; non-GAAP EPS; non-GAAP net income; non-GAAP operating income and margin; non-GAAP gross margin; and free cash flow are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparable GAAP financial measures is included under the heading "Non-GAAP Financial Measures" below. SOUTH JORDAN, Uta

SOUTH JORDAN, Utah, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it will release its financial results for the quarter ended September 30, 2021, after the close of the stock market on Thursday, October 28, 2021. Merit will hold its investor conference call (conference ID 3378476) on the same day (Thursday, October 28, 2021) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). The telephone numbers

Q2 2021 reported revenue of $280.3 million, up 28.4% compared to Q2 2020Q2 2021 constant currency revenue, organic* up 25.5% compared to Q2 2020Q2 2021 GAAP EPS of $0.09, compared to GAAP loss per share of ($0.34) in Q2 2020Q2 2021 non-GAAP EPS* of $0.62, compared to $0.31 in Q2 2020 * Constant currency revenue; constant currency revenue, organic; core revenue; non-GAAP EPS; non-GAAP net income; non-GAAP operating income and margin; non-GAAP gross margin; and free cash flow are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparable GAAP financial measures is included under the heading "Non-GAAP Financial Measures" below. SOUTH JORDAN, Ut